Remove Development Remove Hormones Remove Protein
article thumbnail

FDA accepts AstraZeneca’s NDA for breast cancer combination therapy

Pharmaceutical Technology

The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen. AstraZeneca stated that its NDA is being reviewed under Project Orbis.

HR 245
article thumbnail

New research data on the regulation of hormone-dependent breast cancer

Scienmag

Notch proteins are key regulators of growth and differentiation of both normal and cancer cells. These results can be used in the development of new cancer treatments, especially for hormone-dependent breast cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gut hormone triggers craving for more proteins

Scienmag

Revelations from a fly study could improve our understanding of protein malnutrition in humans.

Protein 52
article thumbnail

Can the FDA keep the momentum going for rare disease drug approvals?

Pharmaceutical Technology

“[In] the last 20 years, there have been a large number of companies that have jumped into the rare disease arena, and for some diseases like Rett syndrome, they have targeted resources to developing therapeutic agents,” he says. T3 is a major hormone in the blood that regulates thyroid levels.

Drugs 317
article thumbnail

New medications for PCOS slowly edge toward development

Pharmaceutical Technology

Scientific research and a better understanding of the condition is driving new developments in medications. The condition’s symptoms are not homogeneous, and that makes drug development complicated,” Javier Szwarcberg, CEO of Spruce Biosciences, a rare disease company researching endocrine disorders, says.

article thumbnail

Is Vegan Casein the Next Big Plant-Based Innovation?

XTalks

Fooditive Group , a plant-based ingredient manufacturer, recently developed a vegan version of casein, one of the main animal proteins in milk. In developing the vegan casein, Fooditive aims to eradicate the downsides of factory farming, antibiotics, hormones and lactose. So, what is casein?

article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. Another pivotal moment in my career was working with Dr.